Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 2Turcot syndrome 1Neoplasms 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

Magnetic Resonance Spectroscopy 6X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Biopsy 5Cyclophosphamide 3ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Temozolomide 2Etoposide 2tazemetostat 1pembrolizumab 1palbociclib 1omburtamab I-131 1olaparib 1etoposide phosphate 1dostarlimab 1abemaciclib 1Vemurafenib 1Triiodothyronine 1Surgical Procedures, Operative 1Sirolimus 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ependymoma × Diffusion Tensor Imaging × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡